Products
Setipiprant
Use and description |
| Setipiprant (INN; developmental code names ACT-129968, KYTH-105) is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan. |
Physical Characters and Index |
Product Name:Setipiprant Other name:KYTH-105, ACT-129968 CAS:866460-33-5 Molecular Formula:C24H19FN2O3 Molecular Weight:402.42 Purity:99% Appearance:White or off-white crystalline powder. |
![1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-phenylbutane-1,4-dione](http://www.owaispharm.com/uploadfile/202507/4a9fd8d7b12add2.png#没有设置高宽参数，将以原图输出)
